Akoya Biosciences — Merger or Acquisition (January 2025)
15 slides from Akoya Biosciences's merger presentation, Jan 10, 2025

Slide 1: First Integrated Solution for Ultra-Sensitive Detection of Blood and Tissue Based Protein Biomarkers
First Integrated Solution for Ultra- Sensitive Detection of Blood and Tissue Based Protein Biomarkers Uniquely positioned to speed up market development of new diagnostic testing solutions January 10, 2025

Slide 2: Important Additional Information
2 IMPORTANT ADDITIONAL INFORMATION In connection with the proposed transaction, Quanterix Corporation (“Quanterix” or “QTRX”) will file with the U.S. Securities and Exchange Commission (the “SEC”) a registration statement on Form S-4 (the “registration statement”), which will contain a joint proxy s

Slide 3: Cautionary Statement Regarding Forward-Looking Statements (Contd.)
3 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS (CONTD.) All forward-looking statements, expressed or implied, included in this presentation are expressly qualified in their entirety by the cautionary statements contained or referred to herein. If one or more events related to these or o

Slide 4: Transaction Overview
Transaction Overview 4 All-stock transaction AKYA shareholders to receive 0.318x QTRX shares per share of AKYA QTRX shareholders to own ~70% of combined entity AKYA shareholders to own ~30% of combined entity AKYA will nominate 2 candidates to join QTRX’s Board of Directors, with the total Board siz

Slide 5: Accelerated Path to Scale and Profitability with Focus on High Growth Markets
Accelerated Path to Scale and Profitability with Focus on High Growth Markets 5 01 Growth 02 Scale 03 Efficiency 04 Acceleration 05 Strong Runway Combined revenue of ~$220M2 Expected strong double-digit organic revenue growth by 2026 Significant annual cost synergies of ~$40M by end of 2026 (~$20M b

Slide 6: Quanterix Today: Leader in Ultra-Sensitive Biomarker Detection
Quanterix Today Leader in Ultra-Sensitive Biomarker Detection 1. Guidance as of November 12, 2024 2. GAAP gross margin guidance range of 57-61%. Projected GAAP gross margin does not include shipping and handling costs, which include freight and other activities costs associated with product shipment

Slide 7: Akoya Biosciences: Leading the Spatial Biology Revolution
Akoya Biosciences Leading the Spatial Biology Revolution 7 Publications Installed Base2024 Revenue Guidance Q1-Q3’24 Non-GAAP Gross Margin1 Established leader with largest install base in market Fastest and most robust platform for tissue biomarker detection Recurring revenue through reagents, softw

Slide 8: Continued Execution of Quanterix's Growth Plan
Continued Execution of Quanterix's Growth Plan 8 02 03 01 Grow Menu Expand into adjacencies Translate into AD Diagnostics • Extend lead position in Neurology biomarkers • Launch first of its kind, novel brain-derived and neuro-inflammatory markers • Extracellular Vesicle (EVs) biomarker detection so

Slide 9: Immediate Opportunity to Increase Serviceable Addressable Market
Immediate Opportunity to Increase Serviceable Addressable Market * Management’s estimate; Excludes Dx and CDx 9 Addition of cutting-edge spatial biology capabilities Technology portfolio addresses customer needs in high growth markets in neurology, oncology and immunology Akoya’s position in oncolog

Slide 10: Uniquely positioned to accelerate market development of new liquid biopsy tests
Uniquely positioned to accelerate market development of new liquid biopsy tests … 10 #1 in Ultra-Sensitive Detection of Biomarkers Track disease progression from tissue to blood #1 in Spatial Phenotyping tools … as liquid biopsy is expected to eventually surpass the market size of all other diagnost

Slide 11: Uniting Clinical and Anatomical Pathology
Uniting Clinical and Anatomical Pathology 11 ü Liquid biopsy to tissue of origin ü Choosing right treatment ü Monitoring of tumor treatment ü Continuous monitoring ü Assess Minimum Residual Disease ü Measure therapy efficacy ü Fewer biopsies First integrated dashboard harmonizing pathologist toolset

Slide 12: Complementary Technology and Service Offerings Expand Commercial Reach
Complementary Technology and Service Offerings Expand Commercial Reach 12 Assay & ReagentsInstruments Lab Testing Services HD-X SR-X SP-X Ultra-sensitive SIMOA Instruments – Benchtop & Sample to Answer Catalog and custom assays in Single-plex and multiplex formats CLIA certified lab with wide menu o

Slide 13: Combined Company: Strong Double-Digit Organic Growth by 2026
Combined Company: Strong Double-Digit Organic Growth by 2026 13 Uniquely positioned to speed market development of new liquid biopsy tests Apply consumables product development engine to accelerate growth of new biomarker pairs across tissue and blood. Suite of synergistic biomarkers already in deve

Slide 14: Significant Cost Synergies
Significant Cost Synergies 14 General and Admin Costs Cost of Goods Combined reagent manufacturing capabilities / infrastructure to improve overall margins Overlap of Corporate, Supply chain and other Support functions offer significant optimization opportunity Footprint Infrastructure Geographical

Slide 15: Uniquely Positioned to Deliver Value
Uniquely Positioned to Deliver Value 15 Significant synergy opportunities across Operations and SG&A Expanded customer relationships & continuum of solution offerings maximize cross-selling opportunities Creates first integrated platform of liquid and tissue biomarkers Unlocks a high-growth $5B1 add
Source: SEC EDGAR · 425 filed Jan 10, 2025




